ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Catabasis, Duchenne UK announce partnership to evaluate edasalonexent in phase 2 non-ambulatory DMD trial
January 13, 2020Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for ... -
Catabasis Announces New Board of Director Appointment
February 18, 2019Catabasis Pharmaceuticals announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors. Dr. Beck has more than 25 years of pharmaceutical development and operations experience and is currently the Executive Vice President... -
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent
September 27, 2018Catabasis announced the initiation of PolarisDMD, the company’s Phase 3 trial for edasalonexent in Duchenne muscular dystrophy (DMD). Edasalonexent inhibits NF-kB, which is the key link between loss of dystrophin and disease pathology and plays a fundamen
Pharma Sources Insight January 2025
